End-of-day quote
Nasdaq
06:00:00 2024-04-24 pm EDT
|
5-day change
|
1st Jan Change
|
0.9601
USD
|
-2.13%
|
|
-1.53%
|
-49.20%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16.89
|
8.703
|
-
|
-
|
Enterprise Value (EV)
1 |
16.89
|
8.703
|
8.703
|
8.703
|
P/E ratio
|
-0.55
x
|
-0.64
x
|
-0.36
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
54.5
x
|
-
|
-
|
-
|
EV / Revenue
|
54.5
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
0
x
|
0
x
|
0
x
|
FCF Yield
|
-
|
133,098%
|
216,498%
|
285,569%
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,936
|
9,018
|
-
|
-
|
Reference price
2 |
1.890
|
0.9650
|
0.9650
|
0.9650
|
Announcement Date
|
4/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.31
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-14.66
|
-16.84
|
-19
|
-30
|
Operating Margin
|
-
|
-4,728.06%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-11.26
|
-16.84
|
-19
|
-29
|
Net income
1 |
-14.41
|
-11.26
|
-14.45
|
-19
|
-29
|
Net margin
|
-
|
-3,633.55%
|
-
|
-
|
-
|
EPS
2 |
-1.380
|
-3.410
|
-1.500
|
-2.700
|
-
|
Free Cash Flow
1 |
-
|
-
|
11,583
|
18,841
|
24,852
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/1/23
|
4/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.122
|
0.188
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-1.75
|
-4.402
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-1,434.43%
|
-2,341.49%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
2.893
|
-4.45
|
-
|
-
|
-
|
-
|
-
|
Net income
|
2.893
|
-4.45
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
2,371.31%
|
-2,367.02%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
0.1900
|
-2.970
|
-0.3900
|
-0.4300
|
-0.5200
|
-0.5600
|
-0.6000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/29/23
|
4/11/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
11,583
|
18,841
|
24,852
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
171
|
254
|
378
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/1/23
|
4/11/24
|
-
|
-
|
-
|
Last Close Price
0.965
USD Average target price
8
USD Spread / Average Target +729.02% Consensus |
1st Jan change
|
Capi.
|
---|
| -49.20% | 8.7M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|